Introduction {#s001}
============

Coronary artery disease (CAD) is one of the leading causes of disease in developed and developing countries. The β~1~-adrenergic receptor (ADRB1) and β~2~-adrenergic receptor (ADRB2) play a pivotal role in the regulation of the cardiovascular system (Dhein *et al.*, [@B4]; Xia *et al.*, [@B16]). There are two major single nucleotide polymorphisms (SNPs) in the *ADRB1* gene: the Ser49Gly (rs1801252) and Arg389Gly (rs1801253) polymorphisms; the *ADRB2* gene exhibits three major SNPs: the Arg16Gly (rs1042713), Gln27Glu (rs1042714), and Thr164Ile (rs1800888) polymorphisms.

Several studies have examined the influence of the *ADRB1* and *ADRB2* polymorphisms on cardiovascular events and all-cause mortality in CAD patients. For example, Zaugg *et al.* ([@B18]) observed that carriers of at least one Gly allele of the *ADRB1* rs1801253 polymorphism showed a greater number of cardiovascular adverse events than Arg homozygotes among CAD patients. However, Li *et al.* ([@B10]) found no relationship between the *ADRB1* rs1801253, *ADRB2* rs1042713, and *ADRB2* rs1042714 polymorphisms and cardiovascular events in Han Chinese patients with CAD.

To better understand the interactions between the *ADRB1* (rs1801252 and rs1801253) and *ADRB2* (rs1042713, rs1042714, and rs1800888) polymorphisms and cardiovascular events as well as all-cause mortality in CAD patients, we undertook a meta-analysis with the aim of obtaining information for individual CAD prognostication and potential clinical application.

Materials and Methods {#s002}
=====================

Search strategy {#s003}
---------------

We carried out a comprehensive search of electronic databases, including PubMed, Ovid, EMBASE, Cochrane, and CINAHL, to identify relevant publications reporting an association between *ADRB1* and *ADRB2* polymorphisms and cardiovascular events as well as all-cause mortality in CAD patients, with the most recent publication date being April 2018. We used the search terms "coronary artery disease (CAD)" or "coronary heart disease (CHD)" or "ischemic heart disease (IHD)" or "myocardial infarction (MI)" or "acute coronary syndrome (ACS)" or "angina pectoris" or "atherosclerosis" or "ASCVD" and "β adrenergic receptor" or "beta adrenergic receptor" or "ADRB" in combination with "polymorphism" or "variation" or "variant" or "allele" or "mutation" or "SNP." Additional relevant publications were identified through manual searches of the bibliographies of the retrieved studies and recent reviews.

Studies that met the following criteria were included: (1) prospective study design with patients who underwent follow-up for more than 1 year; (2) investigation of the association between *ADRB1* and *ADRB2* polymorphisms and cardiovascular events or all-cause mortality in CAD patients among unrelated subjects; (3) diagnosis of CAD based on previous myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting, angiographic evidence, or angina patients with a positive stress test; and (4) the primary outcomes were cardiovascular events or all-cause mortality, wherein cardiovascular events included death, cardiac death, MI, heart failure, unstable angina, coronary revascularization, cardiac hospitalization, stroke, and cerebrovascular insult. Two investigators (Y.L. and H.Y.) screened all eligible studies independently. Any disagreements between the two investigators were resolved through discussion.

Data extraction {#s004}
---------------

Data were extracted from all eligible studies by primary investigators using a standardized extraction form. The following information was collected: first author\'s name, publication year, country, ethnicity of the population studied, age, gender, sample size, polymorphisms, outcomes, duration of follow-up, genotyping methods, Hardy--Weinberg equilibrium (HWE) in controls, quality scores, cases and controls with wild and variant genotypes, risk ratios (RRs), and 95% confidence intervals (95% CIs) of cardiovascular events or all-cause mortality. If any of this information was not provided in the publication, the authors were contacted via e-mail for more detailed data.

Quality assessment {#s005}
------------------

The quality of the identified studies was assessed according to a "methodological quality assessment scale," which was modified from the study by Yuan *et al.* ([@B17]). Five items, including the representativeness of the cases, the source of controls, sample size, quality control of the genotyping methods, and HWE, were evaluated on this scale. The quality scores ranged from 0 to 10, with a high score indicating a good-quality study.

Statistical methods {#s006}
-------------------

The dominant models were evaluated for the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events and all-cause mortality in CAD patients because there were insufficient data for specific cases and controls according to genotype in a few studies. The distribution of the genotypes in the control group was tested for HWE, where *p* \< 0.05 was considered to indicate that the distribution of genotypes in the control group deviated from HWE. RRs and 95% CIs were calculated for the cardiovascular events and all-cause mortality in CAD patients. Statistical heterogeneity between eligible studies was evaluated by using the Cochran\'s Q statistic and *I*^2^ test. *p* \< 0.1 indicated substantial heterogeneity across studies, and a random-effects model was chosen to perform analyses; otherwise, a fixed-effects model was selected. Sensitivity analyses were conducted to evaluate the stability of the results. The leave-one-out method was used to evaluate each study, and a pooled estimate was calculated for the remaining studies. Begg\'s funnel plots were generated to qualitatively evaluate publication bias; Egger\'s test was performed to quantitatively assess the publication bias. All *p* values were two sided. All statistical analyses were performed using STATA software version 11.0 (STATA Corporation, College Station, TX).

Results {#s007}
=======

Study characteristics {#s008}
---------------------

The process of literature retrieval and exclusion is shown in [Figure 1](#f1){ref-type="fig"}. Eight studies were included in our meta-analysis (Lanfear *et al.*, [@B9]; Zaugg *et al.*, [@B18]; Pacanowski *et al.*, [@B12]; Piscione *et al.*, [@B13]; Tseng *et al.*, [@B15]; Li *et al.*, [@B10]; Feldman *et al.*, [@B5]). Women with obstructive CAD (Pacanowski *et al.*, [@B12]), the Heart and Estrogen Replacement Study cohort (Tseng *et al.*, [@B15]), and CAD patients who were treated with β-blockers (Lanfear *et al.*, [@B9]) were enrolled in this meta-analysis. Since two cohorts of patients were enrolled in the study by Feldman *et al.* ([@B5]), the two cohorts were considered as independent studies. A total of 5495 patients from eight studies were included in our meta-analysis. The detailed characteristics of eligible studies included in our meta-analysis are shown in [Table 1](#T1){ref-type="table"}. In the study by Zaugg *et al.* ([@B18]), deviation from HWE was found for the *ADRB1* rs1801253 polymorphism; therefore, we excluded this study from the analysis of the association with cardiovascular events in CAD patients. The specific wild-type/variant patients and the associations of *ADRB1* and *ADRB2* polymorphisms with clinical outcomes according to the eligible studies are shown in [Table 2](#T2){ref-type="table"}.

![Flow diagram of study identification. *ADRB1*, β~1~-adrenergic receptor gene; *ADRB2*, β~2~-adrenergic receptor gene.](fig-1){#f1}

###### 

Characteristics of Studies Included in the Meta-Analysis

  *First author (year)*   *Country*     *Ethnicity*                             *Age (years)*       *Sex (male%)*   *Sample size*   *Polymorphisms*                                         *Outcomes*                                   *Follow-up (years)*   *Method*                                                           *HWE*   *Quality score*
  ----------------------- ------------- --------------------------------------- ------------------- --------------- --------------- ------------------------------------------------------- -------------------------------------------- --------------------- ------------------------------------------------------------------ ------- -----------------
  Zaugg ([@B18])          Switzerland   Caucasian                               NA                  NA              189             rs1801252, rs1042713, rs1042714                         Cardiovascular events                        1                     TaqMan assay                                                       Yes     8
  Li ([@B10])             China         Han Chinese                             NA                  NA              545             rs1801253, rs1042714, rs1042714                         Cardiovascular events                        1                     Sequenom                                                           Yes     7
  Pacanowski ([@B12])     USA           NA                                      62 ± 12             0               227             rs1801253                                               Cardiovascular events, All-cause mortality   5.8                   PCR and single-primer extension, PCR and luciferase-based assays   Yes     8
  Tseng ([@B15])          USA           Caucasian, African American, Hispanic   NA                  0               2223            rs1801252, rs1801253, rs1042713, rs1042714              All-cause mortality                          6.8                   Sequenom                                                           Yes     7
  Lanfear ([@B9])         USA           Caucasian, African-American             60 (12)             64              735             rs1801252, rs1801253, rs1042714                         All-cause mortality                          3                     Applied Biosystems genotyping assays                               Yes     7
  Feldman 1 (2015)        USA           Caucasian                               61.2 (54.8, 69.1)   86.5            532             rs1801252, rs1801253, rs1042713, rs1042714, rs1800888   Cardiovascular events, All-cause mortality   NA                    PCR-RFLP                                                           NA      8
  Feldman 2 (2015)        USA           Caucasian                               62.1 (55.2, 69.3)   86.4            714             rs1801252, rs1801253, rs1042713, rs1042714, rs1800888   Cardiovascular events, All-cause mortality   NA                    PCR-RFLP                                                           NA      8
  Piscione ([@B13])       Italy         NA                                      NA                  NA              330             rs1800888                                               Cardiovascular events                        3 ± 0.33              PCR-RFLP                                                           NA      5

Since two cohorts of patients were enrolled in the study by Feldman *et al.* ([@B5]), the two cohorts were considered as independent studies (Feldman 1 and Feldman 2).

HWE, Hardy--Weinberg equilibrium; NA, not available; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

Association of *ADRB1* and *ADRB2* Gene Polymorphisms with Clinical Outcomes According to Eligible Studies

  *Polymorphism*        *Outcome*               *First author (year)*   *Wild type,* n *(cases/controls)*   *Variants,* n *(cases/controls)*   *RR*         *95% CI*     p
  --------------------- ----------------------- ----------------------- ----------------------------------- ---------------------------------- ------------ ------------ -------
  rs1801252             Cardiovascular events   Feldman 1 (2015)        305/112                             74/41                              0.90         0.70--1.16   0.404
  Feldman 2 (2015)      338/221                 95/59                   1.02                                0.81--1.28                         0.874                     
  Zaugg ([@B18])        NA                      NA                      1.57                                0.82--2.98                         0.170                     
  All-cause mortality   Feldman 1 (2015)        172/245                 43/72                               0.97                               0.69--1.36   0.861        
  Feldman 2 (2015)      162/397                 46/108                  1.02                                0.74--1.42                         0.893                     
  Tseng ([@B15])        NA                      NA                      0.85                                0.63--1.15                         0.300                     
  Lanfear ([@B9])       49/360                  18/129                  1.02                                0.58--1.82                         0.933                     
  rs1801253             Cardiovascular events   Li ([@B10])             23/276                              21/196                             1.05         0.54--2.02   0.887
  Feldman 1 (2015)      198/98                  180/55                  1.23                                1.00--1.50                         0.046                     
  Feldman 2 (2015)      227/141                 206/140                 0.94                                0.78--1.13                         0.511                     
  Pacanowski ([@B12])   35/71                   44/77                   1.16                                0.67--2.01                         0.598                     
  All-cause mortality   Feldman 1 (2015)        110/186                 104/131                             1.16                               0.89--1.52   0.282        
  Feldman 2 (2015)      112/256                 96/250                  0.93                                0.71--1.22                         0.588                     
  Tseng ([@B15])        NA                      NA                      0.96                                0.75--1.23                         0.750                     
  Pacanowski ([@B12])   14/92                   24/97                   1.63                                0.79--3.33                         0.182                     
  Lanfear ([@B9])       38/253                  29/222                  0.87                                0.52--1.46                         0.596                     
  rs1042713             Cardiovascular events   Li ([@B10])             14/185                              27/272                             0.81         0.37--1.77   0.599
  Feldman 1 (2015)      60/22                   319/131                 0.94                                0.71--1.24                         0.661                     
  Feldman 2 (2015)      56/51                   377/230                 1.25                                0.95--1.66                         0.116                     
  All-cause mortality   Feldman 1 (2015)        37/45                   178/272                             0.82                               0.58--1.17   0.281        
  Feldman 2 (2015)      28/79                   180/427                 1.08                                0.73--1.61                         0.702                     
  Tseng ([@B15])        NA                      NA                      1.33                                0.91--1.92                         0.880                     
  Lanfear ([@B9])       82/327                  15/132                  2.21                                1.23--3.97                         0.01                      
  rs1042714             Cardiovascular events   Li ([@B10])             32/378                              12/112                             1.66         0.81--3.42   0.166
  Feldman 1 (2015)      135/51                  244/102                 0.88                                0.72--1.09                         0.248                     
  Feldman 2 (2015)      125/105                 308/176                 1.27                                1.03--1.56                         0.116                     
  Zaugg ([@B18])        NA                      NA                      1.40                                0.73--2.66                         0.310                     
  All-cause mortality   Feldman 1 (2015)        82/104                  133/213                             0.81                               0.62--1.07   0.139        
  Feldman 2 (2015)      56/174                  152/332                 1.29                                0.95--1.75                         0.106                     
  Tseng ([@B15])        NA                      NA                      1.27                                0.97--1.67                         0.086                     
  Lanfear ([@B9])       36/188                  34/308                  0.58                                0.35--0.95                         0.030                     
  rs1800888             Cardiovascular events   Feldman 1 (2015)        368/150                             10/3                               1.14         0.61--2.14   0.679
  Feldman 2 (2015)      420/273                 13/7                    1.02                                0.59--1.78                         0.937                     
  Piscione ([@B13])     NA                      NA                      4.10                                1.95--8.64                         0.0001                    
  All-cause mortality   Feldman 1 (2015)        209/309                 5/8                                 1.19                               0.49--2.89   0.699        
  Feldman 2 (2015)      200/493                 8/12                    1.47                                0.73--2.99                         0.282                     

95% CI, 95% confidence interval; *ADRB1*, β~1~-adrenergic receptor gene; *ADRB2*, β~1~-adrenergic receptor gene; NA, not available; RR, risk ratio.

Association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events {#s009}
---------------------------------------------------------------------------

A positive association was found between the *ADRB2* rs1042714 polymorphism and cardiovascular events in CAD patients (RR = 1.31, 95% CI: 1.08--1.58, *p* = 0.006; [Table 3](#T3){ref-type="table"} and [Fig. 2D](#f2){ref-type="fig"}). Compared with patients who were Gln27 homozygotes, being a Glu27 carrier was associated with a 31% increase in the risk of cardiovascular events. No significant association was found between *ADRB1* (rs1801252, rs1801253), *ADRB2* (rs1042713, rs1800888) and cardiovascular events in CAD patients ([Table 3](#T3){ref-type="table"} and [Fig. 2A--C, E](#f2){ref-type="fig"}).

![Forest plots of the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism. CAD, coronary artery disease; CI, confidence interval; RR, risk ratio.](fig-2){#f2}

###### 

Association of *ADRB1* and *ADRB2* Polymorphisms with Cardiovascular Events and All-Cause Mortality

  *Outcome*               *Polymorphism*   *RR*         *95% CI*                                 p
  ----------------------- ---------------- ------------ ---------------------------------------- -------
  Cardiovascular events   rs1801252        1.00         0.82--1.22                               0.965
  rs1801253               1.07             0.91--1.26   0.389                                    
  rs1042713               1.06             0.85--1.33   0.619                                    
  rs1042714               1.31             1.08--1.58   0.006^[\*](#tf4){ref-type="table-fn"}^   
  rs1800888               1.63             0.73--3.65   0.234                                    
  All-cause mortality     rs1801252        0.95         0.79--1.13                               0.534
  rs1801253               1.02             0.88--1.17   0.816                                    
  rs1042713               1.21             0.85--1.73   0.295                                    
  rs1042714               0.97             0.70--1.35   0.859                                    
  rs1800888               1.36             0.78--2.35   0.281                                    

*p* \< 0.05.

Significant heterogeneity was observed for the associations of *ADRB2* rs1042714 (*I*^2^ = 62.8%) and rs1800888 (*I*^2^ = 79.1%) with cardiovascular events. We performed a random-effects analysis, followed by sensitivity analyses. The results of the sensitivity analyses demonstrated that data from the Feldman 1 study deviated from data from other studies with respect to the association of the *ADRB2* rs1042714 polymorphism and the cardiovascular events ([Fig. 3D](#f3){ref-type="fig"}). After removing this study, *I*^2^ was reduced from 62.8% to 0% (*p* = 0.893). Therefore, we excluded this study from the analysis of the association of the *ADRB2* rs1042714 polymorphism with cardiovascular events. None of the other studies showed deviations with respect to the association of the *ADRB2* rs1800888 polymorphism with cardiovascular events in CAD patients ([Fig. 3E](#f3){ref-type="fig"}).

![Sensitivity analyses of the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism.](fig-3){#f3}

Association of *ADRB1* and *ADRB2* polymorphisms with all-cause mortality {#s010}
-------------------------------------------------------------------------

No significant associations were found between *ADRB1* (rs1801252 and rs1801253) or *ADRB2* (rs1042713, rs1042714, and rs1800888) polymorphisms and all-cause mortality in CAD patients ([Table 3](#T3){ref-type="table"} and [Fig. 4A--E](#f4){ref-type="fig"}).

![Forest plots of the association of *ADRB1* and *ADRB2* polymorphisms with all-cause mortality under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism.](fig-4){#f4}

Significant heterogeneity was found for the association of the *ADRB2* rs1042713 (*I*^2^ = 66.7%) and rs1042714 (*I*^2^ = 76.0%) polymorphism with all-cause mortality. Hence, a random-effects analysis was performed. We did not find any study that deviated from the other studies, as indicated by the sensitivity analyses ([Fig. 5C, D](#f5){ref-type="fig"}).

![Sensitivity analyses of the association of *ADRB1* and *ADRB2* polymorphisms with and all-cause mortality under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism.](fig-5){#f5}

Publication bias {#s011}
----------------

Begg\'s funnel plots ([Figs. 6A--E](#f6){ref-type="fig"} and [7A--E](#f7){ref-type="fig"}) were generated, and Egger\'s tests ([Figs. 8A--E](#f8){ref-type="fig"} and [9A--E](#f9){ref-type="fig"}) were performed to evaluate the potential publication bias. The shapes of the funnel plots showed no evidence of obvious asymmetry. The results of Egger\'s test did not support the existence of publication bias.

![Begg\'s funnel plots of publication bias in the meta-analysis of the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism. logrr, the logarithm of relative risk; s.e. of logrr, standard error of logrr.](fig-6){#f6}

![Begg\'s funnel plots of publication bias in the meta-analysis of the association of *ADRB1* and *ADRB2* polymorphisms with all-cause mortality under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism. logrr, the logarithm of relative risk; s.e. of logrr, standard error of logrr.](fig-7){#f7}

![Egger\'s plots of publication bias in the meta-analysis of the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism.](fig-8){#f8}

![Egger\'s plots of publication bias in the meta-analysis of the association of *ADRB1* and *ADRB2* polymorphisms with all-cause mortality under the dominant model. **(A)** *ADRB1* rs1801252 polymorphism. **(B)** *ADRB1* rs1801253 polymorphism. **(C)** *ADRB2* rs1042713 polymorphism. **(D)** *ADRB2* rs1042714 polymorphism. **(E)** *ADRB2* rs1800888 polymorphism.](fig-9){#f9}

Discussion {#s012}
==========

In the present meta-analysis, we examined whether specific genetic polymorphisms in the *ADRB1* and *ADRB2* genes were associated with cardiovascular events and all-cause mortality in CAD patients. To our knowledge, this was the first meta-analysis to explore the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events and all-cause mortality in CAD patients, and the results suggested that *ADRB2* rs1042714 presented a positive association with cardiovascular events but not with all-cause mortality in CAD patients.

ADRB2 is expressed on coronary endothelial and vascular smooth muscle cells, which play an important role in the vasodilatation of the coronary arteries and microcirculation in normal coronary arteries (Barbato *et al.*, [@B2]; Hesse and Eisenach, [@B6]). Genetic polymorphisms of *ADRB2* have been reported to modulate the functional responses of the receptor to adrenergic stimulation (Dhein *et al.*, [@B4]), which may be associated with cardiovascular events and all-cause mortality in CAD patients. However, conflicting data regarding the association of the *ADRB2* rs1042714 polymorphism with cardiovascular events and all-cause mortality in CAD patients have been reported. Lanfear *et al.* ([@B9]) demonstrated that Glu27 homozygosity at the *ADRB2* rs1042714 polymorphism was a protective factor for overall mortality in CAD patients treated with β-blockers. However, Tseng *et al.* ([@B15]) demonstrated a trend toward increased mortality in Glu27 homozygotes compared to Gln27 carriers among postmenopausal women with CAD, and this finding was further confirmed by the surgical treatment for ischemic heart failure trials. Feldman *et al.* ([@B5]) demonstrated that CAD patients harboring the Glu27 allele of the *ADRB2* rs1042714 polymorphism were at increased risk of mortality and cardiovascular events.

Our data demonstrated that Glu27 carriers at the *ADRB2* rs1042714 polymorphism exhibited an increased risk for cardiovascular events but not all-cause mortality. Potential reasons for this finding include the following: the *ADRB2* rs1042714 polymorphism results in the substitution of Glu for Gln at codon 27, and the "gain-of-function" of the receptor conferred by the Glu27 allele could cause target tissues to be overexposed to catecholamine, thus accelerating the development of CAD and exacerbating heart dysfunction (Barbato *et al.*, [@B1]). In addition, several studies have demonstrated an independent association of the Glu27 allele of the *ADRB2* rs1042714 polymorphism with a number of diseases, such as obesity, dyslipidemia, diabetes, and stroke (Kumar *et al.*, [@B8]). These disorders usually coexist with each other and could lead to development and progression of CAD (Jakovljevic and Ostojic, [@B7]). Lanfear *et al.* ([@B9]) demonstrated that Glu27 homozygosity of the *ADRB2* rs1042714 polymorphism was a protective factor against all-cause mortality only in CAD patients who were treated with β-blockers, whereas they failed to demonstrate any protective effects in patients who were not treated with β-blockers. The reason could be that β-blockers that specifically target ADRB2 might attenuate adverse effects observed in Glu27 carriers at the *ADRB2* rs1042714 polymorphism (McLean *et al.*, [@B11]). Although we concluded that being a Glu27 carrier at the *ADRB2* rs1042714 polymorphism presented a positive association with cardiovascular events, we failed to observe this association for all-cause mortality in CAD patients. A possible explanation for this finding is that the influence of the *ADRB2* rs1042714 polymorphism on cardiovascular clinical outcomes is subtle and therefore might not increase the risk of all-cause mortality, but can still influence cardiovascular events.

No significant associations of the *ADRB1* (rs1801252, rs1801253) and *ADRB2* (rs1042713, rs1800888) polymorphisms with cardiovascular events and all-cause mortality in CAD patients were found. This result was in line with the conclusion of a large prospective cohort study that failed to find any association of the *ADRB1* rs1801253 and *ADRB2* rs1042713 polymorphisms with mortality under an additive model in CAD patients (Cresci *et al.*, [@B3]). Another study that examined the *ADRB2* rs1042713 and rs1800888 haplotype also found no association with revascularization and MI in patients with stable angina undergoing elective PCI (Rywik *et al.*, [@B14]).

Limitations {#s013}
-----------

Although our study was the first meta-analysis to address the association of *ADRB1* and *ADRB2* polymorphisms with cardiovascular events and all-cause mortality in CAD patients, it has some limitations. First, the number of studies involved in our meta-analysis was limited, which rendered the revealed associations less robust. Second, we could not obtain the specific cases and controls according to each genotype of the *ADRB1* and *ADRB2* polymorphisms; hence, we only calculated pooled RRs and 95% CIs under the dominant model. Third, we could not adjudicate causes of death although cardiovascular death is more likely to predominate. Because all-cause mortality instead of cardiovascular death was used for the primary outcome in most studies of this meta-analysis. Fourth, there were differences in the age, gender, and populations of the study cohorts as well as the inclusion and exclusion criteria, cardiovascular events, and duration of follow-up among these studies, which might account for the observed heterogeneity. In the study by Feldman *et al.*, patients with left ventricular dysfunction who present a different risk profile than the cohorts of other studies were enrolled.

In conclusion, this study suggests that *ADRB2* rs1042714 polymorphism might play a role in the prognosis of cardiovascular events and ultimately represent as an important genetic marker. CAD patients harboring the *ADRB2* rs1042714 polymorphism may need aggressive management to optimize their prognosis.
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